Prosecution Insights
Last updated: August 17, 2026

Examiner: ROMERO, KRISTEN WANG

Tech Center 1600 • Art Units: 1624 1625 1626

This examiner grants 71% of resolved cases

Performance Statistics

70.7%
Allow Rate
+10.7% vs TC avg
71
Total Applications
+30.0%
Interview Lift
1171
Avg Prosecution Days
Based on 41 resolved cases, 2023–2026

Rejection Statute Breakdown

4.4%
§101 Eligibility
21.7%
§102 Novelty
20.3%
§103 Obviousness
37.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18718781 ABL INHIBITORS AND USES THEREOF Non-Final OA The Regents of the University of California
17932466 2-BETA-NAPHTHYL-ACETIC ACID ANALOGS AS AKR1C3 INHIBITORS AND METHODS OF USING SAME Non-Final OA VANDERBILT UNIVERSITY
18605320 Compositions of Azadirachta Indica and Methods of Treating Cancer Non-Final OA Board of Regents, The University of Texas System
18572979 PHENOLIC COMPOUNDS SUBSTITUTED WITH NON-RADIOACTIVE ISOTOPES AND USES THEREOF Non-Final OA SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
18768262 COMPOUNDS FOR THE TREATMENT OF GLYCOGEN STORAGE DISORDERS Non-Final OA RAMOT AT TEL-AVIV UNIVERSITY LTD.
18719260 METHODS FOR THE SYNTHESIS OF COMPLEMENT FACTOR D INHIBITORS AND INTERMEDIATES THEREOF Non-Final OA Alexion Pharmaceuticals, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month